#Investors: Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance. Press release: go.novartis.social/4cCsrje IR Webcast: go.novartis.social/4cL7uBm #NVSQ126 $NVS $NOVN

#NVSQ126 Novartis social media posts on Q1 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ126 Novartis social media posts on Q1 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

On Tuesday, April 28, Novartis will announce its Q1 2026 results. Register to listen here: novartis.social/6017vGJTc #NovartisNews $NVS $NOVN #NVSQ126

#Investors: Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 Press release: go.novartis.social/3ZTwccA IR Webcast: go.novartis.social/4aaJF4D #NVSQ425

#NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information. #NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis. $NVS $NOVN

On Wednesday, February 4 Novartis will announce its Q4 and Full-Year 2025 results. Register to listen here: go.novartis.social/45NqoVz #NovartisNews $NVS $NOVN #NVSQ425

Delighted to announce the extension of the @WHO–@Novartis memorandum of understanding, continuing the provision of free multidrug therapy for #leprosy treatment and expanding support to include funding for single-dose rifampicin for post-exposure prophylaxis.   For 25 years, WHO and Novartis have partnered to interrupt the transmission and eliminate leprosy disease.   In 2024, #Jordan became the first country verified and acknowledged by WHO for elimination of leprosy showing when science, equity and partnership are aligned, disease elimination becomes within reach.   Thank you Novartis for your continued support and I look forward to further expand our collaboration to promote #HealthForAll. who.int/news/item/21-01-2026…

#News: Today marks a milestone in our $23 billion US expansion plan, as we announce the opening of a state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, CA. 🔗 go.novartis.social/47LONem

In Q3 2025, Novartis delivered solid sales and core operating income growth with strong pipeline progress. Our key growth drivers performed well, and we had important innovation milestone achievements including an FDA approval and positive data readout that has the potential to underpin our growth through 2030 and beyond. novartis.social/6018t8JRE #NVSQ32025

On Tuesday, October 28 Novartis will announce its Q3 2025 earnings. Register to listen here: novartis.social/6010tBbaI #NovartisNews $NVS $NOVN #NVSQ32025

#News: @US_FDA approval of our new oral, targeted therapy for #ChronicSpontaneousUrticaria brings new hope for patients and underlines our commitment to making bold progress in immunology. 🔗go.novartis.social/474jV9C

This #WorldHeartDay, we’re celebrating The FIT Stop event in Madrid. Inspired by the analogy of a car’s engine & the human heart, we invited citizens to partake in fun and educational activities to encourage awareness of cardiovascular health. Let’s protect our hearts & help others do the same. Together, we can make a difference. #Cardiology #HeartHealth #NoHeartLostTooSoon #WorldHeartDay2025

September is a month of reflection and momentum in #hematology – a time to recognize those affected by chronic blood cancers and disorders, and to advocate for the progress still needed so patients can live life well. 🎥 Here's how we’re driving change:

Madrid is calling and we’ve arrived for #ESCCongress! The Novartis team is on the ground and ready to engage in bold conversations, share cutting-edge science, and explore the future of cardiovascular care. Visit our full event page here.novartis.social/6013sbuw7 #Cardiology #HeartHealth #NoHeartLostTooSoon

Dominic Brittain, our Senior Global Program Head, CRM Development, is looking ahead to what promises to be an inspiring weekend at @escardio #ESCCongress 2025, where we’re presenting new data in cardiovascular disease.

Novartis delivered a strong Q2 25 with double-digit sales growth and core margin expansion. We advanced our pipeline, and key launches are accelerating. We upgraded our FY 25 core operating income guidance and remain confident in our mid- to long-term growth outlook. go.novartis.social/4lGw9dO #NVSQ22025

On Thursday, July 17 Novartis will announce its Q2 2025 earnings. Register to listen here: go.novartis.social/4nIq029 #NovartisNews $NVS $NOVN #NVSQ22025

#News: We’re excited to announce our upcoming oncology and hematology data that has been recently accepted at @ASCO Annual Meeting and @eha_hematology 2025 Congress. #ASCO25 #EHA2025. go.novartis.social/3YL3ECf

Novartis had a strong Q1 2025 with double-digit sales growth, robust margin expansion and significant pipeline progress, including 3 new product approvals. We upgraded our full-year guidance and remain focused on advancing our pipeline and achieving our growth outlook. go.novartis.social/3RBDQ7B #NVSQ12025

On Tuesday, April 29 Novartis will announce its Q1 2025 earnings. Register to listen here: go.novartis.social/4lJVS5h #NovartisNews $NVS $NOVN #NVSQ12025